ArticleClinical and translational medicine2020
Trans-omic profiling between clinical phenoms and lipidomes among patients with different subtypes of lung cancer.
Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Advances in Oral Cavity Stem Cell Research Revealed through Multi-omics Analysis.Stem cell reviews and reports · 2026Review
- Lipidomic signatures as predictive biomarkers for early-onset lung cancer: Identification and development of a risk prediction model.Journal of advanced research · 2026Article
- Lipidomics reveals effect of EHHADH in lung squamous cell.Cell biology and toxicology · 2025Article
- Exploring the genetic causal inference between plasma lipidome and lung carcinoma: a bidirectional mendelian randomization study.Discover oncology · 2025Article
- Associations between lipids and lung cancer subtypes.Discover oncology · 2025Article
- Early potential metabolic biomarkers of T1 stage lung adenocarcinoma based on serum metabolomics.Frontiers in molecular biosciences · 2025Article
- ZNF32 histidine 179 and 183 single-site and double-site mutations promote nuclear speckle formation but differentially regulate the proliferation of breast cancer cells.Frontiers in cell and developmental biology · 2025Article
- Deciphering the lipid-cancer nexus: comprehensive Mendelian randomization analysis of the associations between lipid profiles and digestive system cancer susceptibility.Lipids in health and disease · 2024Article
- Roles of glutamic pyruvate transaminase 2 in reprogramming of airway epithelial lipidomic and metabolomic profiles after smoking.Clinical and translational medicine · 2024Article
- Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer.Cell biology and toxicology · 2024Article
- Causal association of plasma lipidome with lung carcinoma and mediating role of inflammatory proteins: evidence from Mendelian randomization analysis.Journal of Cancer · 2024Article
- Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients.Journal of lipids · 2024Article
- Novel lipidomes profile and clinical phenotype identified in pneumoconiosis patients.Journal of health, population, and nutrition · 2023Article
- Regulatory roles of external cholesterol in human airway epithelial mitochondrial function through STARD3 signalling.Clinical and translational medicine · 2022Article
- Forward single-cell sequencing into clinical application: Understanding of ageing and rejuvenation from clinical observation to single-cell solution.Clinical and translational medicine · 2022Article
- Lipids and genes: Regulatory roles of lipids in RNA expression.Clinical and translational medicine · 2022Article
- Quantitative metabolic fluxes regulated by trans-omic networks.The Biochemical journal · 2022Review
- Clinical challenges of tissue preparation for spatial transcriptome.Clinical and translational medicine · 2022Article
- New focuses on roles of communications between endoplasmic reticulum and mitochondria in identification of biomarkers and targets.Clinical and translational medicine · 2021Review
- Clinical significance of spatiotemporal transcriptional bursting and control.Clinical and translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer has high mortality, often accompanied with systemic metabolic disorders. The present study aimed at defining values of trans-nodules cross-clinical phenomic and lipidomic network layers in patients with adenocarcinoma (ADC), squamous cell carcinomas, or small cell lung cancer (SCLC). We measured plasma lipidomic profiles of lung cancer patients and found that altered lipid panels and concentrations varied among lung cancer subtypes, genders, ages, stages, metastatic status, nutritional status, and clinical phenome severity. It was shown that phosphatidylethanolamine elements (36:2, 18:0/18:2, and 18:1/18:1) were SCLC specific, whereas lysophosphatidylcholine (20:1 and 22:0 sn-position-1) and phosphatidylcholine (19:0/19:0 and 19:0/21:2) were ADC specific. There were statistically more lipids declined in male, <60 ages, late stage, metastasis, or body mass index < 22 . Clinical trans-omics analyses demonstrated that one phenome in lung cancer subtypes might be generated from multiple metabolic pathways and metabolites, whereas a metabolic pathway and metabolite could contribute to different phenomes among subtypes, although those needed to be furthermore confirmed by bigger studies including larger population of patients in multicenters. Thus, our data suggested that trans-omic profiles between clinical phenomes and lipidomes might have the value to uncover the heterogeneity of lipid metabolism among lung cancer subtypes and to screen out phenome-based lipid panels as subtype-specific biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.